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Objective: To study the microflora in patients with Helicobacter pylori  infection during treatment with orneprazole 
alone and in combination with amoxycillin, t o  study transmission of relapsing H. pylori  strains by fingerprinting and to  
investigate if H. pylori  is detectable in saliva and dental plaque by polymerase chain reaction (PCR). 
Methods: Twenty-eight dyspeptic patients with ff. pyloriinfection were divided into two treatment groups: omeprazole 
20 m g  plus arnoxycillin 1000 mg, or omeprazole 20 m g  plus placebo twice a day for 14 days. Biopsies were taken before, 
during and after treatment. The biopsies were cultivated in  order to study the commensal microflora and H. pylori  PCR 
was used to  detect H. pylori  in the biopsies, saliva and dental plaque. The H. pylori  strains were fingerprinted with 
arbitrary primed PCR. 
Results: Twenty-five patients harbored H. pylori, of whom 22 also harbored a normal mucosal microflora. ff. pyloriwas 
present in all patients in the omeprazole-placebo group and in 39% of the patients in the omeprazole-amoxycillin group 
4 weeks after treatment. There were no significant differences in the number of bacteria in  antrum and corpus. 
Conclusions: There was an inverse relationship between the growth of commensal microflora and H. pylori during 
treatment in both groups. H. pylori  was detectable in  saliva and dental plaque by PCR. The original H. pylori  strain was 
present in all but one relapsing patient. 
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INTRODUCTION 
The normal gastrointestinal microflora exists under 
physiologic conditions which are stable within the 
individual and is important for maintaining the 
ecological balance in the body. This balance may be 
disturbed by administration of antimicrobial agents [l]. 
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One such disturbance is overgrowth of already present 
microorganisms, such as yeasts, which may produce 
systemic infections in immunocompromised patients, 
and Clostridium d@cile, which may lead to severe 
diarrhea or colitis. A second disturbance is the 
reduction of colonization resistance, i.e. the resistance 
displayed by the host to implantation of new micro- 
organisms in the normal microflora. A third effect is 
the development of antimicrobial resistance among 
bacteria in the normal microflora. Peroral administra- 
tion of amoxycillin has previously been shown to 
cause moderate ecological disturbances in the intestinal 
tract, with overgrowth of amoxycillin-resistant entero- 
bacteria [2]. Establishment of resistant strains, either by 
selection of intrinsically resistant microorganisms or 
by selection of bacteria with acquired resistance, is a 
common finding after antimicrobial therapy. Several 
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antimicrobial agents have the ability to act as inducers 
and promote a temporary increase in levels of bacterial 
drug-inactivating enzymes. The human gastrointestinal 
microflora is a huge reservoir of potentially pathogenic 
microorganisms which, under certain circumstances, 
may translocate and cause infection in other sites of the 
body. 
The healthy gastric mucosa is often colonized by 
the indigenous microflora but contains very few micro- 
organisms in healthy individuals, due to the low pH. 
The microorganisms are probably protected from the 
gastric acid by the mucous layer. Impaired gastric 
secretion may cause proliferation of acid-tolerant 
organisms such as streptococci, lactobacilli and micro- 
cocci [3] .  If the pH is permanently above 4, proliferation 
of other microorganisms such as enterococci, entero- 
bacteria and bacteroides can take place [4,5]. These 
microorganisms colonize the mucosa without any signs 
of mucosal inflammation, in contrast to Helicobacter 
pylori [5]. 
The finding of Helicobacterpylori is clearly associated 
with gastritis and peptic ulcer disease. The route of 
transmission is not yet known, although Helicobacter 
pylori is suggested to be spread via contaminated water 
or person-to-person transmission. The bacteria have 
been identified &om saliva and dental plaque with PCR 
[6]. The bacteria have also been found in drinking 
water [7]. It has been suggested that there is a coccoid 
form of the bacterium which may spread and there- 
after colonize when the environment improves [8] .  
Complete eradication of Helicobacter pylori is known to 
heal chronic active gastritis rapidly and cure associated 
peptic ulcer disease. There are several suggested treat- 
ment regimens for Helicobacter pylori infection: dual 
therapy with a proton pump inhibitor and antibiotics 
such as amoxycillin, and triple therapy with a proton 
pump inhibitor in combination with metronidazole 
and amoxycillin or clarithromycin. 
Omeprazole is a substituted benzimidazole that 
acts as a potent acid suppressor in the stomach. It 
inhibits the activity of the proton pump, H+/K+- 
ATPase, located in the parietal cells. Omeprazole is 
absorbed in the proximal intestine and reaches the 
parietal cells of the stomach through the bloodstream 
In the present study, the ecological effects on the 
gastric mucosal microflora of proton pump inhibitor 
alone and in combination with amoxycillin were 
studied, Transmission within the individual was also 
studied by detecting Helicobacter pylori in saliva and 
dental plaque samples with PCR. Reinfecting strains 
from the mucosa were fingerprinted and compared 
with strains before treatment in order to investigate 
transmission. 
[91. 
Patients and study design 
Twenty-eight patients referred for gastroscopy at the 
Department of Surgery, Huddinge University Hospital, 
Karolinska Institute, Stockholm, Sweden, and who 
were positive for Helicobacter pylori, were included in 
the study. The patients had not been treated with 
omeprazole or any antibiotics for at least 1 month prior 
to the study. To be included, gastric biopsies &om the 
patients had to be positive in a rapid urease test (CLO, 
Delta West Ltd, Australia), later confirmed by histo- 
pathologic examination, culture or PCR. Cultivation 
of Helicobacter pylori or at least two other positive tests 
were considered to establish a true infection. The 
patients were randomized into two treatment groups. 
Fourteen patients were given oral treatment with 20-mg 
omeprazole capsules (Losec, Astra, Sweden) and 1000 
mg of amoxycillin given as two capsules (Amoxicillin 
Scand Pharm, ScandPharm, Sweden) twice a day, and 
14 patients were treated with 20-mg omeprazole capsules 
(Losec, tktra, Sweden) and placebo twice a day for 14 
days. The omeprazole-amoxycillin group consisted of 
eight men and six women (mean age 55.1 years, range 
22-78), and the omeprazole-placebo group consisted 
of seven men and seven women (mean age 58.6 years, 
range 2t;-81). There were no statistical differences 
between the two groups concerning age, sex or endo- 
scopic diagnosis. The study was randomized, and 
double bmlind. Biopsies (four from the antrum and four 
from the corpus), saliva and dental plaque samples were 
collected. on three separate occasions, before the start 
of the study (day O), during the treatment (day 10) and 
4 weeks after medication had been stopped (day 42). 
Biopsies from one of the patients in the 
omeprazole-placebo group were not obtained on day 
10, and the follow-up samples from one of the patients 
in the annoxycillin group were also missing. 
The study was approved by the Local Ethics 
Committee at Huddinge University Hospital, Karolinska 
Institute, Stockholm, Sweden. 
Biopsies ,from antrum and corpus 
Fresh biopsies were subjected to the rapid urease 
test (CLO, Delta West, Australia), and biopsies for 
cultivation and PCR, were fi-ozen until processed. 
Amoxycilr'in concentration 
The concentrations of amoxycillin in the gastric 
biopsies were determined by the agar well method 
(IsoSensitest agar, pH 7.4, Oxoid, UK). Biopsies 
were weighed and homogenized in 1 mL of brain- 
heart infusion broth (BHI). The agar plates were 
incubated at 37OC for 18 h and the detection limit was 
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0.25 mg/L. The indicator strain was Micrococcus lutea 
ATCC 9341. The concentrations of amoxycillin were 
determined in relation to diameters of inhibition zones 
caused by known concentrations of amoxycillin from 
standard series. Positive controls were included and 
each sample assay was performed in duplicate. 
Cultivation 
One biopsy from each location was placed in 1 mL 
of BHI, immediately stored at -70OC and thereafter 
processed as follows: the specimen was thawed, weighed, 
and homogenized, and a 10-fold serial dilution was 
prepared to 100 pL ofeach dilution was inoculated 
onto agar plates. 
Blood agar plates were used for cultivation of total 
aerobic and anaerobic microflora by aerobic incubation 
at 37OC for 24 h and anaerobic incubation at 37OC for 
48 h in anaerobic jars (GasPak, BBL, Switzerland). 
Chocolate agar plates were used for cultivation of 
fastidious microorganisms and the plates were incubated 
in 6% COz for 24 h. For detection of Helicobacterpylori, 
two different agar plates were used; brucella agar 
supplemented with menadione (1 mg/L) and brucella 
agar supplemented with 5% sheep blood, vancomycin 
(6 mg/L), nalidixic acid (20 mg/L), amphotericin 
B (2 mg/L) and menadione (1 mg/L). The plates 
were incubated in a micro-aerophilic environment 
(CampyPak, BBL, USA) at 37OC for 5 days. 
Aerobic and anaerobic bacteria were identified as 
described by Heimdahl and Nord [lo]. Differences 
in numbers of a particular microorganism of 2 log 10 or 
greater were considered to represent a significant change 
[ 1 11. Identification of Helicobacter pylori was confirmed 
by colony appearance, Gram-staining, and positive 
urease, oxidase, and catalase tests. 
Histopa thologic evaluation 
The biopsies for histopathologic examination were 
fixed in phosphate-buffered formalin (4%, pH 7.49) 
and stained by standard methods with hematoxylin and 
eosin, and a modified Giemsa staining. The presence or 
absence of Helicobacter pylori was determined by an 
experienced pathologist. 
PCR 
DNA extraction and P C R  were performed on one 
biopsy from each individual and from each location 
according to the method previously described by Stark 
et al [12]. To perform the DNA extraction, 10 pL of 
the biopsy homogenate was placed in 400 pL of 
Chelex-100 (Bio-Rad, USA) and 20 pL of proteinase 
K (1 mg/mL) at 65OC for 60 min, boiled for 10 min 
and centrifuged (14008) for 10 min. The supernatant 
was used for P C R  with the primer set JW21 (5'-CGC 
ACC TGC TGG AAC ATT AC-3') and JW22 (5'- 
CGT TAG CTG CAT TAC TGG AGA-3')[12]. A 
138-bp-long fragment of the 16s rRNA was amplified 
1131, and the products were then visualized on a 1% 
ethidium-bromide-stained agarose gel. 
Genomic fingerprinting 
An arbitrary primed P C R  (AP-PCR) was performed 
in order to study the genomic fingerprinting of the 
Helicobacter pylori isolates before and after treatment. 
One colony of Helicobacter pylori was lysed in 10 pL of 
lysis buffer at  60°C for 45 min and then neutralized in 
10 pL of neutralizing buffer from the Sputum Sample 
Preparation Kit (Roche, Switzerland). The samples 
were frozen until P C R  was performed. 
A primer of 19 bp with the sequence 5'-CAC 
TCG TCG GGA ATGC CCT-3' was used and the 
P C R  program was as follows: 95OC for 3 min, 40 cycles 
of 94OC for 30 s, 37OC for 1 min, and 72OC for 1 min; 
and 72OC for 5 min [14]. 
The P C R  fragments were run on a 1% ethidium- 
bromide-stained gel, at 65 V for 4 h. 
Saliva and dental plaque samples 
The dental plaque samples were placed in 1 mL of 
BHI. The samples were immelately frozen at -70OC. 
After the samples were thawed, the DNA was extracted 
by the cetyltrimethyl-ammonium bromide (CTAB) 
method according to the miniprep protocol of Wilson 
1151. The pellet of DNA was redissolved in 50 pL of 
Tris-EDTA buffer. P C R  was performed with primers 
amplifying a segment of the 16s rRNA gene of 
Helicobacter pylori: primer JW21, which is the upstream 
primer (5'-GCG ACC TGC TGG AAC ATT AC-3'; 
nucleotides 691-710), and primer JW22, which is the 
downstream primer (5'-CGT TAG CTG CAT TAC 
TGG AGA-3'; nucleotides 829-809) 1131. The P C R  
product was visualized on a 1% ethidium-bromide- 
stained agarose gel. 
RESULTS 
The microflora of the stomach 
No amoxycillin was detected in the gastric biopsies. 
The normal microflora of the stomach before treatment 
was cultivated in 22 of the 28 patients. I t  consisted 
mainly of: Streptococcus spp., Staphylococcus spp., Micro- 
coccus spp., Neisseria spp., Haemophilus spp., Entero- 
bacteriaceae, Peptostreptococcus spp., Actinomyces spp., 
Killonella spp. and Bacteroides spp. (Table 1). The 
compositions of the microflora in the antrum and 
the corpus were similar and there were no sign- 
ficant differences between the two treatment groups. 
Yeasts were, however, present in two patients in 
Table 1 
14 days, 
The normal gastric microflora (antrum and corpus) before (day 0), during (10) and after (day 42) adrmnistration of omeprazole 20 mg twice a day and amoxycillin 1 g twice a day for 
and omeprazole 20 mg twice a day and placebo for 14 days 
Omeprazoleamoxycillin group Omeprazole-placebo group 
no Day0 0-10 nlo Day 10 #42 Day42 0-42 no Day0 0-10 n lo  Day 10 n42 Day 42 i342 
Streptococcus salivarius 
Streptococcus sanguis 
Streptococcus milleri 
Streptocows mitior 
Staphylococcus spp. 
Micrococcus 
Neisseria spp. 
Haemophilus spp. 
Enterobacteriaceae 
Yeasts 
Anaerobic Gram- 
positive cocci 
Lactobacillus and 
~~ Rifidohnrtwium ............. spp. 
Actinomyces spp. 
Killonella spp. 
Bacteroides spp. 
Fusobacterium spp. 
Propionibacterium 
Anaerobic Gram- 
positive rods 
14 
11 
8 
14 
13 
11 
13 
8 
4 
3 
11 
7 
12 
13 
6 
2 
4 
6 
3.3 (<2 .M.4)  
3.2 (<2.0-6.3) 
2.4 (<2.0-5.5) 
3.4 (<2.M.3) 
<2.0 (<2.0-4.4) 
<2.0 (<2.0-5.8) 
<2.0 (<2.&3.0) 
<2.0 (<2.0-3.7) 
< 2.0 
< 2.0 
3.0 (<2.0-6.3) 
2.7 (<2.&4.3) 
2.8 (<2.0-6.9) 
3.0 (<2.0-5.4) 
2.4 (<2.&5.9) 
< 2.0 
<2.0 (<2.@8.0) 
<2.0 (<2.0-5.4) 
-0.9 
-1.2 
2.2 
2.0 
1.5 
0 
3.2 
2.0 
1.7 
1.4 
1.6 
0.5 
1.7 
1.1 
1.8 
0.7 
0 
1.4 
14 
11 
8 
14 
13 
11 
13 
8 
4 
3 
11 
7 
12 
13 
6 
3 
4 
6 
2.4 (<2.0-6.8) 
4.6 (<2.0-6.5) 
3.5 (<2.0-5.2) 
<2.0 (<2.0-4.8) 
< 2.0 (< 2.0-6.6) 
5.4 (<2 .M.0)  
5.2 (2.7-5.6) 
4.0 (3.7-5.5) 
3.7 (3.7-3.7) 
3.4 (<2.0-5.3) 
4.6 (<2.0-5.7) 
".- 3 (<2.0-4.0) 
4.5 (C2.M.1)  
4.4 (<2.&5.6) 
4.1 (<2.&4.3) 
2.7 (<2.0-4.0) 
<2.0 (<2.&3.6) 
3.4 (<2.&5.0) 
13 
10 
8 
13 
12 
11 
12 
8 
4 
3 
11 
6 
12 
13 
6 
3 
3 
6 
2.7 (<2.0-6.8) 
2.7 (C2.M.4) 
2.9 (<2.&5.0) 
3.7 (<2.0-5.9) 
2.5 (<2.0-4.6) 
3.5 (<2.0-5.5) 
<2.0 (<2.0-5.3) 
< 2.0 
<2.0 
3.3 (<2.0-4.9) 
3.2 (<2.0-6.1) 
2.6 (C2.W.3) 
4.0 (<2.0-6.6) 
3.6 (<2.&5.9) 
2.4 (<2.&3.7) 
<2.0 (<2.&3.0) 
3.5 (2.7-4.0) 
<2.0 
-0.6 
-0.5 
0.6 
0.3 
0.2 
1.5 
0 
0 
0 
1.3 
0.2 
-0.1 
1.2 
0.6 
0 
0 
1.5 
0 
14 
11 
11 
14 
11 
12 
7 
7 
2 
2 
14 
8 
13 
11 
10 
5 
5 
10 
3.2 (<2.M.5) 
<2.0 (<2.M.1) 
<2.0 (<2.&5.1) 
3.9 (<2.0-6.5) 
3.3 (<2.i34.7) 
3.6 (C2.CS.8) 
<2.0 (<2.&5.0) 
<2.0 
<2.0 
3.4 (2.7-4.2) 
<2.0 (<2.0-5.6) 
3.5 (i2.G-5.5) 
3.8 (<2.0-5.8) 
2.7 (<2.0-5.6) 
<2.0 (<2.0-4.5) 
<2.0 
3.4 (<2.0-4.9) 
3.4 (<2.&5.0) 
3.1 
0 
3.2 
2.7 
0.6 
1.9 
2.5 
3.1 
3.2 
0.6 
2.7 
0.3 
1.8 
3.3 
2.7 
2.8 
0.3 
1.9 
13 
11 
10 
13 
10 
12 
7 
7 
2 
2 
13 
7 
12 
10 
10 
5 
5 
9 
6.3 (12.0-7.5) 
<2.0 (<2.&7.3) 
5.3 (<2.0-6.7) 
6.6 (<2.&7.3) 
3.9 (<2.0-5.5) 
4.5 (<2.0-5.8) 
5.1 (<2.0-6.2) 
5.2 (4.M.4) 
4.0 (4.0-4.0) 
5.5 (<2.0-6.2) 
4.7 (i2.0-6.2) 
9 Q f H 9  L r  3\ 
J." , .&." ".A, 
5.6 (12.M.4) 
6.0 (<2.M.8) 
4.7 (<2.&5.7) 
3.7 (<2.0-4.7) 
4.8 (4.2-5.9) 
5.3 ( i 2 . M . 5 )  
14 
11 
11 
14 
11 
12 
7 
7 
2 
2 
14 
8 
13 
11 
10 
5 
5 
10 
4.5 (<2.0-6.8) 
3.4 (<2 .M.3)  
3.2 ((2.0-6.3) 
4.9 (<2.M.3) 
4.2 (<2.0-4.7) 
< 2.0 (< 2.0-5.6) 
2.7 (<2.&5.2) 
<2.0 
4.5 (4.4-4.6) 
<2.0 (<2.0-4.2) 
3.2 (<2.0-6.1) 
3.: (:2.w.;) 
3.5 (<2.&5.7) 
4.6 (<2.0-5.7) 
<2.0 (<2.0-5.0) 
c2.0 
<2.0 (<2.0-5.3) 
<2.0 (<2.0-3.7) 
1.3 
1.4 
1.2 
1 .o 
-1.3 
0.6 
0 
0.7 
0 
1.1 
1.2 
0 
-0.3 
1.9 
0 
0 
-1.4 
-1.4 
n 0,10.42, number of patients with detectable levels of microorganisms; Day 0, 10, 42, median (minimum-maximum) of log values of the number of microorganisms per mL saliva; 0-10, differences in log values f b m  
day 0 until day 10; 0-42, differences in log values fiom day 0 until day 42. 
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the placebo group and in none of the patients in the 
omeprazole-amoxycdin group. Twenty-five of the 
28 patients had cultivable Helicobacter pylori before 
treatment. 
The commensal microflora in the omepra- 
zole-placebo group increased significantly during 
treatment. The changes were more pronounced in the 
corpus than in the antrum. Figures 1 and 2 show the 
alteration of the microflora in the corpus. Significant 
increases in the aerobic microflora were seen, namely 
Streptococcitr salivarius, Streptococcus milleri, Streptococcus 
mitior, Neisseria spp. and Huemophilus spp. Anaerobic 
microorganisms such as anaerobic Gram-positive rods, 
Veillonella spp., Bacteroides spp. and Fusobacterium spp. 
increased significantly in numbers during treatment 
(Table 1). The mean number of Helicobacter pylori 
organisms decreased markedly during treatment, with 
no significant difference between the antrum and the 
corpus (Figure 1). 
Four weeks after treatment the normal flora was 
almost back to pretreatment levels (Table 1). Helicobacter 
pylovi was cultivated from gastric biopsies in 12 of 14 
patients. However, Helicobacrer pylori was also deter- 
mined by other methods such as histology, PCR and 
a 
0 
CJ 
i 
0 
m 
.- 
L c
m 
m 
0 -
l o t  
CLO. According to those findings, Helicobacter pylori 
was present in all patients 4 weeks after treatment with 
omeprazole and placebo. 
The normal microflora increased in density during 
treatment in the omeprazole-amoxycillin group, but 
to a lesser extent compared to patients receiving 
omeprazole plus placebo. There were no significant 
differences between the antrum and the corpus (Figure 
2). In the aerobic flora significant increases were seen 
among Streptococcus milleri, Streptococcus mitior, Neisseria 
spp. and Huemophilus spp. None of the patients had 
detectable levels of yeasts at day 0, but three patients 
were colonized by yeasts at day 10. In the anaerobic 
microflora an overall increase was noticed but no 
species showed any significant increase (Table 1). 
Four weeks after treatment (day 42), some altera- 
tions in the numbers of bacteria were seen as compared 
with day 0 (Table 1). The patients who were colonized 
with yeasts during treatment still had detectable levels 
of yeasts at  day 42. 
Four patients were colonized with Helicobacterpylori 
after treatment. According to the other methods, 
Helicobacter pylori was present in five of the 14 patients 
in this group. The eradication rate of Helicobacter pylori 
8 
6 
+ 
0 
8 
0) 
0 -
Before During 
treatment treatment 
After 
treatment 
Before During 
treatment treatment 
After 
treatment 
Figure 1 Htdicoburter pylori (---o---) and the total number 
of aerobic and anaerobic microflora (-+-), with mean 
values, in the gastric mucosa from the corpus, in patients 
treated with omeprazole 20 mg twice a day and placebo 
twice a day for 14 days. The detection limit was 10’ 
CFU/mL. After treatment = 42 days. 
Figure 2 Htlirobucter pylnri (---o---) and the total numbers 
of aerobic and anaerobic microflora (-+-), with mean 
values, in the gastric mucosa from the corpus, in patients 
treated with omeprazole 20 mg twice a day and amoxycdin 
1 g twice a day for 14 days. The detection limit was 10’ 
CFU/mL. 
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was 61% among the patients treated with 20 mg of 
omeprazole twice a day plus 1000 mg of amoxycillin 
twice a day for 14 days. 
Eradication of Helicobacter pylori 
The presence of Helicobacter pylori was also determined 
on separate biopsies by CLO test, histology and PCR. 
The levels of Helicobderpylori at day 10 in the omeprazole- 
placebo group, tested by the different methods, were: 
56% with CLO test, 50% by histology and 92% by 
PCR. In the amoxycillin group the figures were lower: 
7% by CLO test and histology and 23% by PCR. 
Four weeks after treatment, Helicobacter pylori was 
detected by CLO test in 100% and by histology 
and PCR in 92% of the omeprazoleplacebo group, 
whereas in the omeprazoleamoxycillin group Helico- 
bacter pylori was detected in 33% of the samples with 
CLO test, 31% with histology and 54% with PCR. 
Fingerprinting of Helicobacter pylori strains 
Seven patients who were Helicobacter pylori positive 
(by CLO test, cultivation, histology and PCR) before 
treatment were shown to be Helicobacter pylori negative 
in all tests during treatment, but Helicobacter pylori 
positive in all tests 4 weeks after treatment. Three 
patients belonged to the omeprazole-placebo group 
and four belonged to the omeprazole-amoxycillin 
group. !;trains from the antrum and corpus of these 
seven patients were fingerprinted by the use of AP- 
PCR. The identical fingerprints were present before 
and after treatment in all but two patients, one ofwhom 
A, is shown in Figure 3. One patient had different 
strains in the antrum and the corpus before treatment, 
and only the corpus strain was found after treatment 
(data noit shown). Another patient was found to harbor 
a new strain in the corpus after treatment, while the 
antral strain was identical to the one found before 
treatment (patient D). The fingerprints from four 
patients, A-D, are shown in Figure 3. 
Helicobacterpylori in dental plaque and saliva 
Sixtyfour per cent (9/14) of the patients in the 
omeprazole-placebo group had PCR-detectable Helico- 
bacter pylori in saliva and/or dental plaque before 
Figure 3 AP-PCR of Helicobacter pylori strains isolated from four patients. Lanes 1-8 represent strains from patients included 
in the omeprazole-amoxycillin group, patients A and B. Lanes 1-4: strains from patient A, from antrum (lanes 1 and 3) and 
corpus (lanes 2 and 4), before (lanes 1 and 2) and after (lanes 3 and 4) treatment. Lanes 5-8: strains &om patient B, from 
antrum (lanes 5 and 7) and corpus (lanes 6 and 8), before and after treatment. Lanes 9-15 represent strains &om two patients 
(C and D) in the omeprazole-placebo group. Lanes 9-11: patient C, strains from antrum (lane 9) and corpus (lane 10) 
before treatment, and &om antrum (lane 11) after treatment. Lanes 12-15: strains from antrum (lanes 12 and 14) and corpus 
(lanes 13 and 15), before and after treatment from patient D. 
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treatment. During treatment, the same number of 
Helicobacter pylori-positive patients were seen in this 
group. After treatment, 93% (13/14) had positive 
Helicobacter pylori in saliva and/or dental plaque. Four 
patients had detectable Helicobacter pylori in saliva, four 
in dental plaque, and five in both saliva and dental 
plaque. 
In the omeprazole-amoxycillin group, Helicobacter 
pylori was detected in 69% (9/13) before treatment, and 
in 85% (11/13) during treatment. All patients had 
detectable Helicobacterpylori in their saliva and/or dental 
plaque at day 42. Five patients had Helicobacter pylori in 
the saliva, two in dental plaque and six in both saliva 
and dental plaque. 
DISCUSSION 
Several studies have shown that administration of anti- 
microbial agents often causes quantitative and quali- 
tative changes in the normal microflora [16]. In the 
present study, the normal microflora of the stomach was 
investigated under the influence of omeprazole and 
amoxycdlin. 
No amoxycillin was observed in the gastric 
biopsies, which might be due to the 100-fold dilution 
of the biopsies when placed in 1 mL of BHI for 
transportation. It has previously been reported that 
peroral administration of 1000 mg of amoxycillin 
results in concentrations ranging from 0.01 to 1.71 
mg/kg in gastric biopsies 30 min after administration 
Elevation of the gastric pH has been shown to 
cause bacterial overgrowth in the stomach [18]. In the 
present study, the total numbers of microorganisms 
increased in the stomach during treatment in both 
study groups, probably due to the increase in pH 
resulting from the omeprazole treatment. The increase 
in the numbers of microorganisms was more pro- 
nounced in the placebo group, which indicates that 
amoxycillin has a significant suppressive effect on the 
normal flora. It has also been suggested that amoxycillin 
is more effective at a neutral pH [19]. The impact 
of amoxycillin on the gastric microflora has, to our 
knowledge, not been studied previously, while several 
previous investigators have shown that amoxycillin has 
a suppressive effect on the normal intestinal microflora 
[16,20,21]. 
In the present study biopsies from both the antrum 
and the corpus were cultivated. No significant differences 
were seen between the two locations. 
The alterations in the numbers of Helicobacter pylori 
did not follow the pattern of the other microorganisms 
during treatment. Helicobacter pylori decreased signifi- 
cantly in both groups during treatment. There was an 
~ 7 1 .  
inverse relationship between the total numbers of 
microorganisms (other than Helicobacter pylon] and the 
numbers of Helicobacter pylori organisms in the gastric 
microflora. This might be due to the colonization 
resistance expressed by the normal gastric microflora, 
the difference in susceptibility to pH changes, or a 
specific antimicrobial effect of omeprazole on Helico- 
bacterpylori in vivo. In a study by Sjostedt et al [ 5 ] ,  there 
was a trend of increased numbers of microorganisms 
on the gastric mucosa, except Helicobacter pylori, with 
increasing intragastric pH. Helicobacter pylori did, how- 
ever, decrease with increasing pH, in accordance with 
our findings. Nakao et a1 [22] have shown in vitro 
that omeprazole has a specific bactericidal effect on 
Helicobacter pylori, resulting in an MIC9o value of 
25 mg/L. 
Helicobacterpylori was not cultivable from any of the 
subjects in the omeprazole-amoxycillin group during 
treatment, while six patients in the omeprazole- 
placebo group had detectable Helicobacter pylori at day 
10. 
The presence of Helicobacter pylori was detected 
with PCR, with the primer set JW 21/JW 22. This 
primer set has been shown to have a high sensitivity and 
specificity by Weiss et a1 [13], although one cannot 
exclude the possibility that another, not yet identified, 
microorganism could have been amplified. 
Based on CLO, histology, cultivation and PCR, six 
patients in the omeprazole-amoxycillin group had no 
detectable Helicobacter pylori in the stomach at day 42. 
However, all six patients had PCR-detectable Helico- 
bacter pylori in their saliva or dental plaque at this time. 
This could be an indication of the mouth being a 
reservoir for Helicobacter pylori. 
In the group of patients ( n  =7) without detectable 
Helicobacter pylori on day 10 and detectable Helicobacter 
pylori on day 42, the strains were evaluated with AP- 
PCR in order to verifi- if the original strain of 
Helicobacter pylori had recolonized the stomach or if 
the patient had established a new Helicobacter pylori 
infection. Since the identical strain was detected before 
and after treatment, it seems reasonable to believe that 
Helicobacter pylori is present somewhere else in the 
patient’s body. The question arises of where and in 
what shape the bacteria survive. One hypothesis is that 
the bacteria survive intracellularly in the gastric mucosa 
and are therefore out of reach of the present detection 
methods. Another hypothesis is that the bacteria survive 
elsewhere in the body, e.g. in the saliva or dental 
plaque. 
All seven patients had detectable Helicobacter pylori 
in the saliva or in the dental plaque during treatment. 
However, this was true for 75% of all patients in the 
present investigation, and it may therefore not be a 
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significant observation. Helicobacter pylori seemed to be 
present more often in saliva and dental plaque after and 
during treatment than before (96%, 74% and 67%). 
This may indicate that Helicobacter pylori migrates to 
the mouth when suppressed or eradicated from the 
stomach. Cultivation of Helicobacter pylori from saliva 
and dental plaque has not yet been reported, probably 
due to overgrowth of other microorganisms. 
In conclusion, the commensal microflora of the 
stomach increases in numbers in patients with Helico- 
bacterpylori infection during treatment with omeprazole 
and omeprazole in combination with amoxycillin, while 
the numbers of Helicobacter pylori organisms decrease. 
Helicobacterpylori can be detected in the saliva and dental 
plaque of infected dyspeptic patients. In patients with 
relapsing Helicobacter pylori infection, the reinfection 
seems often to be caused by the original Helicobacter 
pylori strain, indicating that Helicobacter pylori escapes 
treatment by a so far unknown mechanism. 
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